United States Imposes 100 Percent Tariff on Indian Generic Drugs Threatening $9.7 Billion Export Flow

India's Generic Exports face a steep new U.S. duty that could wipe out the $9.7 billion value of Indian generic medicines shipped to the United States, analysts warn the measure may cut export volumes sharply.

U.S. Tariff Policy sets a 100 percent levy on all imported generic drugs while carving out exemptions for a limited list of Indian specialty medicines, including select oncology and rare‑disease treatments, a move officials say targets patent‑protected products.

Industry Impact could see major Indian manufacturers like Sun Pharma and Cipla lose market share in the United States, prompting some firms to explore alternative markets, adjust pricing strategies, or risk price hikes for U.S. patients.

Export Figures show Indian pharma shipments already surpass $31 billion worldwide despite global headwinds, driven by strong demand for affordable medicines, highlighting the sector’s scale but also its vulnerability to sudden policy shifts.